2021
DOI: 10.1016/j.jaad.2020.10.075
|View full text |Cite
|
Sign up to set email alerts
|

Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
19
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(19 citation statements)
references
References 5 publications
0
19
0
Order By: Relevance
“…Thus, as data are still scarce and as patients treated with anti-CD20 drugs are in general at higher risk for infections, the use of RTX during the pandemic has to be carefully pondered on a case-by-case basis (2,7). Moreover, in the view of the recent development of COVID-19 vaccines, RTX treatment could be preferably considered at least 4 weeks after a complete vaccine cycle (34).…”
Section: Discussionmentioning
confidence: 99%
“…Thus, as data are still scarce and as patients treated with anti-CD20 drugs are in general at higher risk for infections, the use of RTX during the pandemic has to be carefully pondered on a case-by-case basis (2,7). Moreover, in the view of the recent development of COVID-19 vaccines, RTX treatment could be preferably considered at least 4 weeks after a complete vaccine cycle (34).…”
Section: Discussionmentioning
confidence: 99%
“…To date, despite the lack of evidence about the safety and efficacy of COVID-19 vaccines on IBD patients as this cohort has (15,16).…”
Section: Inflammatory Bowel Diseasesmentioning
confidence: 99%
“…We recommend to timely schedule COVID-19 vaccination in autoimmune bullous disease patients treated with rituximab. Similarly to influenza vaccine recommendations, patients who have not started rituximab need to be vaccinated ≥ 4 weeks prior to rituximab infusion, while patients under rituximab need to be vaccinated 12-20 weeks after completion of a treatment cycle (Table 1) (15).…”
Section: Cutaneous Diseasesmentioning
confidence: 99%
“…However, some of the disease modifying therapies (DMTs) used for MS could hamper the immune response necessary for developing immunity against SARS-CoV-2 [7][8][9][10]. As with any other vaccine, in MS patients each decision needs to be taken individually after a thorough consideration of the potential risks and benefits [11][12][13][14][15][16].…”
Section: Vaccines Against Sars-cov-2 Have Not Been Used In Ms Patientmentioning
confidence: 99%